There’s nothing quite like a powerful pharma company hiding need-to-know information from a vulnerable group and potentially making billions in return. Here’s the scoop:
Taxotere and its generic version Docetaxel: No indication that’s it’s any more effective than comparable chemo drugs on the market and a strong risk of one potentially permanent side effect — all over, full body hair loss or balding.
Meanwhile, “The Other Drugs:” hair loss may occur during chemotherapy but hair tends to regrow soon after treatment.
So why weren’t you told the difference?
You know how it goes, because we’ve heard this story before. Taxotere costs patients more than a pretty penny, and it made its manufacturer a fortune. So for twenty years, things kept chugging. Women were prescribed Taxotere, not told the risk of permanent hair loss. Doctors prescribed Taxotere, not told the risk of permanent hair loss. And meanwhile there may have always been a less expensive, equally effective option — with no permanent reminder of your cancer included.
Maddening, right? You bet. That’s why we’re women helping women learn their legal options. Change won’t come unless we speak up to power and say NO MORE! If you were hurt, take action.
At the end of the day, this is about your right to choose and look after your body — at the most critical time. When you were already fighting cancer with all you had, Taxotere may have just dug that knife in deeper — and WHY?